DESTINY-Gastric01 was a randomized, open-label, phase II trial that investigated T-DXd versus physician’s choice of chemotherapy in patients with HER2-positive (HER2+) gastric cancer or GEJ cancer that had progressed in response to at least two previous therapies (2). The gene discussed is ERBB2; the disease is gastric cancer.